- Previous Close
40.70 - Open
41.25 - Bid 40.50 x --
- Ask 40.60 x --
- Day's Range
40.10 - 41.25 - 52 Week Range
25.40 - 46.50 - Volume
111,237 - Avg. Volume
322,213 - Market Cap (intraday)
1.705B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-0.04 - Earnings Date --
- Forward Dividend & Yield 0.20 (0.71%)
- Ex-Dividend Date Aug 9, 2023
- 1y Target Est
--
Taiwan Biomaterial Co., Ltd. engages in the development and sale of medical devices in Taiwan. The company provides Foamagen, a foamy dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and the nickel-titanium guidewire for guiding cerebral vascular surgery; and tissue repair and regeneration products for the treatment of early osteoarthritis. Taiwan Biomaterial Co., Ltd. Was founded in 2010 and is based in Zhubei, Taiwan.
www.twbm.com.twRecent News: 6649.TWO
View MorePerformance Overview: 6649.TWO
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6649.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6649.TWO
View MoreValuation Measures
Market Cap
1.71B
Enterprise Value
1.45B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.66
Price/Book (mrq)
2.72
Enterprise Value/Revenue
15.01
Enterprise Value/EBITDA
90.61
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.55%
Return on Assets (ttm)
-2.19%
Return on Equity (ttm)
-2.85%
Revenue (ttm)
65.53M
Net Income Avi to Common (ttm)
-18.05M
Diluted EPS (ttm)
-0.04
Balance Sheet and Cash Flow
Total Cash (mrq)
290.21M
Total Debt/Equity (mrq)
9.48%
Levered Free Cash Flow (ttm)
-42.74M